Ionis Targets Ultra-Rare Disease Market With Zilganersen

 
• By Alaric DeArment
  
Ionis announced positive results from its Phase I-III study of zilganersen in Alexander disease. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D